Search Results

Arcellx, Inc. announced that management will participate in two upcoming investor conferences.

Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported business highlights and financial results for the first quarter ended March 31, 2024.

Arcellx, Inc. and Kite, a Gilead Company, announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.

Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.

Anito-cel has shown no signs of delayed neurotoxicity at around 9 months of follow-up, hinting at a safety profile that could set it apart from J&J and Legend’s Carvykti.

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety profile—will help differentiate the CAR T therapy from Legend Biotech and J&J’s entrenched Carvykti in relapsed and refractory multiple myeloma.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET.

Arcellx, Inc. (NASDAQ: ACLX) today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.